1156 15th Street, NW, Suite 200 Washington DC 20005 Phone: 202-659-3306 Fax: 202-659-3859 Email: firstname.lastname@example.org
Send a Message
HISTORY OF CiPA
The CiPA initiative began following a workshop in July 2013 at the US FDA. The objective of the CIPA initiative is to engineer an assay for assessment of the proarrhythmic potential of new drugs that has improved specificity compared with the hERG assay plus Thorough QT study.
HESI can provide more details
about CiPA and CiPA workstreams.